Research ArticleOriginal Article

PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas

Junling Shen, Jilong Yang, Lei Sang, Rui Sun, Weiyu Bai, Chao Wang, Yan Sun and Jianwei Sun
Cancer Biology & Medicine August 2022, 19 (8) 1211-1223; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0294

References

  1. 1.↵
    2. Tsao H,
    3. Atkins MB,
    4. Sober AJ.
    Management of cutaneous melanoma. N Engl J Med. 2004; 351: 998–1012.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.
    2. Song X,
    3. Zhao Z,
    4. Barber B,
    5. Farr AM,
    6. Ivanov B,
    7. Novich M.
    Overall survival in patients with metastatic melanoma. Curr Med Res Opin. 2015; 31: 987–91.
    OpenUrl
  3. 3.↵
    2. Debarbieux S,
    3. Duru G,
    4. Dalle S,
    5. Beatrix O,
    6. Balme B,
    7. Thomas L.
    Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol. 2007; 157: 58–67.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Siegel R,
    3. Naishadham D,
    4. Jemal A.
    Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10–29.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    2. Hauschild A,
    3. Grob JJ,
    4. Demidov LV,
    5. Jouary T,
    6. Gutzmer R,
    7. Millward M, et al.
    Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380: 358–65.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    2. Eroglu Z,
    3. Chen YA,
    4. Gibney GT,
    5. Weber JS,
    6. Kudchadkar RR,
    7. Khushalani NI, et al.
    Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma. Clin Cancer Res. 2018; 24: 5516–24.
    OpenUrlAbstract/FREE Full Text
  7. 7.
    2. Smalley KS,
    3. Flaherty KT.
    Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer. 2009; 100: 431–5.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Paraiso KH,
    3. Haarberg HE,
    4. Wood E,
    5. Rebecca VW,
    6. Chen YA,
    7. Xiang Y, et al.
    The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012; 18: 2502–14.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    2. Paraiso KH,
    3. Das Thakur M,
    4. Fang B,
    5. Koomen JM,
    6. Fedorenko IV,
    7. John JK, et al.
    Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015; 5: 264–73.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    2. Manzano JL,
    3. Layos L,
    4. Buges C,
    5. de Los Llanos Gil M,
    6. Vila L,
    7. Martinez-Balibrea E, et al.
    Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med. 2016; 4: 237.
    OpenUrl
  11. 11.↵
    2. Linder S.
    The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. Trends Cell Biol. 2007; 17: 107–17.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.
    2. Wolf K,
    3. Wu YI,
    4. Liu Y,
    5. Geiger J,
    6. Tam E,
    7. Overall C, et al.
    Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol. 2007; 9: 893–904.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    2. Murphy DA,
    3. Courtneidge SA.
    The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol. 2011; 12: 413–26.
    OpenUrlCrossRefPubMed
  14. 14.↵
    2. Seals DF,
    3. Azucena EF Jr.,
    4. Pass I,
    5. Tesfay L,
    6. Gordon R,
    7. Woodrow M, et al.
    The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell. 2005; 7: 155–65.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    2. Artym VV,
    3. Zhang Y,
    4. Seillier-Moiseiwitsch F,
    5. Yamada KM,
    6. Mueller SC.
    Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res. 2006; 66: 3034–43.
    OpenUrlAbstract/FREE Full Text
  16. 16.
    2. Yamaguchi H,
    3. Lorenz M,
    4. Kempiak S,
    5. Sarmiento C,
    6. Coniglio S,
    7. Symons M, et al.
    Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol. 2005; 168: 441–52.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    2. Oser M,
    3. Yamaguchi H,
    4. Mader CC,
    5. Bravo-Cordero JJ,
    6. Arias M,
    7. Chen X, et al.
    Cortactin regulates cofilin and N-WASp activities to control the stages of invadopodium assembly and maturation. J Cell Biol. 2009; 186: 571–87.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    2. Gao C,
    3. Chen G,
    4. Kuan SF,
    5. Zhang DH,
    6. Schlaepfer DD,
    7. Hu J.
    FAK/PYK2 promotes the Wnt/beta-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3beta. Elife. 2015; 4: e10072.
  19. 19.↵
    2. Zhang Y,
    3. Moschetta M,
    4. Huynh D,
    5. Tai YT,
    6. Zhang Y,
    7. Zhang W, et al.
    Pyk2 promotes tumor progression in multiple myeloma. Blood. 2014; 124: 2675–86.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    2. Genna A,
    3. Lapetina S,
    4. Lukic N,
    5. Twafra S,
    6. Meirson T,
    7. Sharma VP, et al.
    Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells. J Cell Biol. 2018; 217: 375–95.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    2. Sun J,
    3. Lu F,
    4. He H,
    5. Shen J,
    6. Messina J,
    7. Mathew R, et al.
    STIM1- and Orai1-mediated Ca(2+) oscillation orchestrates invadopodium formation and melanoma invasion. J Cell Biol. 2014; 207: 535–48.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    2. Sun J,
    3. He H,
    4. Pillai S,
    5. Xiong Y,
    6. Challa S,
    7. Xu L, et al.
    GATA3 transcription factor abrogates Smad4 transcription factor-mediated fascin overexpression, invadopodium formation, and breast cancer cell invasion. J Biol Chem. 2013; 288: 36971–82.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    2. Keeley T,
    3. Lin S,
    4. Lester DK,
    5. Lau EK,
    6. Yang S.
    The fucose salvage pathway inhibits invadopodia formation and extracellular matrix degradation in melanoma cells. PLoS One. 2018; 13: e0199128.
  24. 24.↵
    2. Yin Q,
    3. Jian Y,
    4. Xu M,
    5. Huang X,
    6. Wang N,
    7. Liu Z, et al.
    CDK4/6 regulate lysosome biogenesis through TFEB/TFE3. J Cell Biol. 2020; 219: e201911036.
  25. 25.↵
    2. Sun Y,
    3. Yokoi K,
    4. Li H,
    5. Gao J,
    6. Hu L,
    7. Liu B, et al.
    NGAL expression is elevated in both colorectal adenoma-carcinoma sequence and cancer progression and enhances tumorigenesis in xenograft mouse models. Clin Cancer Res. 2011; 17: 4331–40.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    2. Lu F,
    3. Sun J,
    4. Zheng Q,
    5. Li J,
    6. Hu Y,
    7. Yu P, et al.
    Imaging elemental events of store-operated Ca(2+) entry in invading cancer cells with plasmalemmal targeted sensors. J Cell Sci. 2019; 132: jcs224923.
  27. 27.↵
    2. Eleniste PP,
    3. Bruzzaniti A.
    Focal adhesion kinases in adhesion structures and disease. J Signal Transduct. 2012; 2012: 296450.
  28. 28.↵
    2. Meads MB,
    3. Fang B,
    4. Mathews L,
    5. Gemmer J,
    6. Nong L,
    7. Rosado-Lopez I, et al.
    Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma. Oncogene. 2016; 35: 2723–34.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords